ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoantigens"

  • Abstract Number: 0948 • ACR Convergence 2025

    Presentation of Apoptotic Cell-Derived Autoantigens in Systemic Autoimmune Disease

    Lance Peterson1, Hannah KL De Cleene2, Cheryl Lichti2, David Bending3 and Kodi Ravichandran2, 1Rheumatology and Immunology, Pediatrics, Washington University School of Medicine, St. Louis, MO, 2Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, 3Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, England, United Kingdom

    Background/Purpose: Systemic lupus erythematosus is a chronic, multisystem autoimmune disease characterized by the dysregulated clearance of dying cells, which results in the release of damage-associated…
  • Abstract Number: 0924 • ACR Convergence 2025

    Human Serum Albumin Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Bind Multiple Scavenger Receptors and Alter Cellular Morphology

    Lauren Klingemann1, Michael Duryee1, Nozima Aripova1, Wenxian Zhou2, Hannah Johnson1, Breanna Butler1, Carlos Hunter1, Ted Mikuls1 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Bellevue, NE

    Background/Purpose: Post-translational modifications (PTMs) of self-proteins are implicated in the pathogenesis of rheumatoid arthritis (RA). The PTMs, malondialdehyde-acetaldehyde (MAA), citrulline (CIT), and the co-modification of…
  • Abstract Number: 0923 • ACR Convergence 2025

    Influenza Virus Infection Alters the MHC Class II Self-Immunopeptidome to Present Lupus-Associated Autoantigens

    Julia Rood1, Stephanie Suh Kyung Yoon2, Mary Heard1, Michael Hogan2, Nicola Ternette3, Edward Behrens4 and Laurence Eisenlohr1, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3University of Dundee, Dundee, Scotland, United Kingdom, 4CHOP, West Chester, PA

    Background/Purpose: Viral infections and major histocompatibility complex class II (MHC II) are both implicated in the genesis of systemic lupus erythematosus (SLE), but a mechanistic…
  • Abstract Number: 0921 • ACR Convergence 2025

    Fibrinogen Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Promotes Pro-Inflammatory Macrophage Differentiation Through p38 and NF-κB Signaling

    Hannah Johnson1, Wenxian Zhou2, Michael Duryee1, Carlos Hunter1, Geoffrey Thiele1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Bellevue, NE

    Background/Purpose: Citrulline (CIT) and malondialdehyde-acetaldehyde (MAA) co-adduct native proteins in RA tissues to create a dual pro-inflammatory and pro-fibrotic milieu. Our previous work demonstrated that…
  • Abstract Number: 2652 • ACR Convergence 2025

    Anti-mitochondrial antibodies in systemic sclerosis target enteric neurons and are associated with GI dysmotility

    Zsuzsanna McMahan1, Srinivas Puttapaka2, Livia Casciola-Rosen3, Timothy Kaniecki3, Laura Gutierrez3, Su Hong MIng2, Philippa Seika2 and Subhash Kulkarni4, 1UT Health Houston, Houston, TX, 2BIDMC/Harvard, Boston, MA, 3Johns Hopkins University, Baltimore, MD, 4BIDMC, Boston, MA

    Background/Purpose: Most patients with systemic sclerosis (SSc) experience gastrointestinal (GI) dysmotility. The enteric nervous system (ENS) regulates GI motility, and its dysfunction causes dysmotility. A…
  • Abstract Number: 0900 • ACR Convergence 2025

    Profiling of Novel Autoantibodies for Prediction of Disease Activity in ANCA-Associated Vasculitis

    Charlotta Preger1, Maria Aspenberg1, Metta Berenpas1, Armita Dwivedi2, Juliana Bordignon Draibe3, Peter Nilsson1, Mark A. Little2 and Elisa Pin1, 1Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden, 2Trinity Kidney Centre, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland, 3Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain

    Background/Purpose: ANCA-associated vasculitides (AAV) are a heterogenous group systemic autoimmune diseases characterized by necrotizing inflammation of small blood vessels requiring prompt initiation of immunosuppressive treatment…
  • Abstract Number: 2528 • ACR Convergence 2025

    Broad Screening of the Human Proteome Identifies a Cassette of Six Autoantigens that Distinguishes IgG4-Related Disease

    Federica Bonaso1, Zhenrui Zhang2, Mahilan Guha3, Ian Doyle4, Jesse Akaa4, Grace McMahon5, Isha Jha5, Sydney Montesi5, Thomas Guy6, Guy Katz5, Zachary Wallace7, John Stone8, Vinay S. Mahajan9, Shiv Pillai10 and Cory Perugino11, 1University of Brescia, ASST Spedali Civili of Brescia, Massachusetts General Hospital, Monza, Italy, 2Ragon Institute of Mass General Brigham, MIT, and Harvard, Boston, 3Montgomery Blair High School, Brigham and Women’s Hospital, Boston, 4Massachusetts General Hospital (MGH - Mass General) (MGB), Boston, MA, 5Massachusetts General Hospital, Boston, MA, 6Ragon Institute of MGH, MIT and Harvard/ Royal Prince Alfred Hospital Sydney, Sydney, Australia, 7Massachusetts General Hospital, Newton, MA, 8Massachusetts General Hospital , Harvard Medical School, Concord, MA, 9Brigham and Women's Hospital, Boston, MA, 10Harvard Medical School, Cambridge, MA, 11Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic immune-mediated disease typified by mass-forming lesions. Self-antigens driving the oligoclonal expansion of plasmablasts have previously been reported. However,…
  • Abstract Number: 0617 • ACR Convergence 2025

    Autoantibodies to Extracellular Antigens in Lupus Patients Serum Versus Controls; Predominance of Autoantibodies to Type I Interferons in Lupus Sera

    Kathryn Counts1, Dulaney Wilson2, Leon Furchtgott3 and Gary Gilkeson1, 1Medical University of South Carolina, Charleston, SC, 2Medical University of South Carolina, Charleston, 3SeraNova Bio, Boston, MA

    Background/Purpose: Key features in the pathophysiology of SLE include cytokine dysregulation and autoantibody production. Traditional autoantibody testing in SLE is primarily limited to intracellular antigens…
  • Abstract Number: 2386 • ACR Convergence 2025

    Anti-Trim72 Auto-antibodies In Systemic Lupus Erythematosus Patients and a Lupus Mouse Model with Myocarditis Compromise Membrane Repair in Mouse & Human Cardiomyocytes

    Braden Zeno1, Shane Bruckner2, kassidy Banford3, Hannah Bulgart4, Stacy Ardoin5, noah weisleder4 and Wael Jarjour6, 1Ohio State University, upper arlington, OH, 2OSU, Columbus, OH, 3Loyola University Chicago, Columbus, OH, 4University of Kentucky, Lexington, KY, 5Nationwide Children's Hospital, Columbus, OH, 6The Ohio State University, Columbus, OH

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that causes inflammation in many of the body’s tissues, including the heart. Recent studies attribute…
  • Abstract Number: 0888 • ACR Convergence 2025

    TargetScan Platform Identifies Targets of CD8+ T cells in Ankylosing Spondylitis and Birdshot Uveitis

    Adam S. Weinheimer1, Olivia Pryor2, Catalina Burbano3, Tyler Heath3, Livio Dukaj3, Shoshana M.K. Bloom3, Jackson Lirette3, Rachel Lent3, Prachi Dhanania3, Nicole A. Ladd3, Ryan Kritzer3, Hana Husic3, Shobitha Jillella3, Alexander Cristofaro2, Chandan K. Pavuluri3, Jenna LaBelle3, Laurie Barefoot3, Shrikanta Chattopadhyay3, Andrew P. Ferretti3 and Cagan Gurer3, 1TScan Therapeutics, Boston, MA, 2TScan Therapeutics, Waltham, 3TScan Therapeutics, Waltham, MA

    Background/Purpose: Antigen-specific therapies offer a promising approach to selectively modulating autoimmune responses without broad immunosuppression. Strong associations with specific Class I HLA alleles in ankylosing…
  • Abstract Number: 2027 • ACR Convergence 2025

    Development of a multi-disease panel for autoimmune diseases

    Charlotta Preger, Maria Aspenberg, Metta Berenpas, Peter Nilsson and Elisa Pin, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden

    Background/Purpose: Autoantibodies serve as important biomarkers for diagnosing autoimmune diseases. However, current clinical assays for their detection often face challenges, such as uncertainty about the…
  • Abstract Number: 0886 • ACR Convergence 2025

    A First-in-Class Biologic Selectively Targeting HLA-B27-Reactive T Cells in Ankylosing Spondylitis

    Patrick Holec, Megan Reitars, Nishant Singh and Isabelle Larsen, Fletcher Biosciences, Cambridge, MA

    Background/Purpose: Ankylosing spondylitis (AS), a chronic autoimmune disease strongly associated with HLA-B27:05, is currently managed with therapies that broadly suppress inflammation instead of targeting disease-driving…
  • Abstract Number: 1858 • ACR Convergence 2025

    Antinuclear Antibodies from Systemic Sclerosis Patients Enter Cells via a Clathrin Endocytosis Mechanism and Interact with their Intracellular Antigen.

    Aurélien Chepy1, Marie-Elise Martel1, Solange Vivier1, Meryem Tardivel2, Antonino Bongiovanni2, Marie Mistretta1, Maxime Secq1, Lucile Guilbert3, Eric HACHULLA4, Sylvain Dubucquoi5, David Launay1 and Vincent Sobanski1, 1Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institut de Recherche Translationnelle en Inflammation, Lille, France., Lille, France, 2Univ. Lille, BioImaging Center Lille-Nord de France (BICeL), Lille, France., Lille, France, 3CHU Lille, Institut d'Immunologie, Lille, France., Lille, France, 4CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, France, Lille, France, 5Univ. Lille, Inserm, CHU Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, Lille, France ; CHU Lille, Institut d’Immunologie, Lille, France, Lille, France

    Background/Purpose: Antinuclear autoantibodies (ANA) are robust biomarkers for the diagnosis and prognosis of systemic sclerosis (SSc), but their role in pathogenesis is still uncertain. Recent…
  • Abstract Number: 0862 • ACR Convergence 2025

    In immune-mediated necrotising myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis

    Margherita Giannini1, Giulia Quiring2, Mustapha Oulad-Abdelghani3, Béatrice Lannes1, Yves Allenbach4, Olivier Benveniste5, Olivier Boyer6, Aleksandra Nadaj Pakleza1, Bernard Geny7 and Alain Meyer8, 1Strasbourg University Hospital, Strasbourg, France, 2University of Strasbourg, Strasbourg, France, 3IGBMC, Strasbourg, France, 4SORBONNE UNIVERSITE, Paris, France, 5Sorbonne Uniersite, Hopital de la Pitie-Salpetriere, Paris, France, 6University of Rouen, Rouen, France, 7UR 3072, Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; FranceExplorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg;, Strasbourg, Alsace, France, 8Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, UR 3072, Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; France, Strasbourg, Alsace, France

    Background/Purpose: The aim of this study was to investigate whether in immune-mediated necrotising myopathy (IMNM), anti-HMGCR antibodies interfere with HMGCR activity and have a myopathic…
  • Abstract Number: 1779 • ACR Convergence 2025

    Citrullinated and Malondialdehyde-Acetaldehyde Modified Fibrinogen Activates Macrophages and Induces Inflammatory Responses in Coronary Endothelium

    Wenxian Zhou1, Hannah Johnson2, Michael Duryee2, Engle Sharp2, Carlos Hunter2, Tate Johnson2, Mabruka Alfaidi2, Daniel Anderson3, Kishore Bidasee2, Geoffrey Thiele2 and Ted Mikuls2, 1University of Nebraska Medical Center, Bellevue, NE, 2University of Nebraska Medical Center, Omaha, NE, 30587964, Durham, NC

    Background/Purpose: Endothelial cell (EC) dysfunction is a key driver of cardiovascular (CV) complications in rheumatoid arthritis (RA), yet mechanisms underlying EC dysfunction in RA are…
  • 1
  • 2
  • 3
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology